Molecular Biomedicine(国际期刊)(可官网投稿)

Molecular Biomedicine(一年1卷),杂志于2020年创办,经新闻出版总署批准的正规刊物,是由世界著名的科技期刊出版公司Springer Nature和四川省国际医学交流促进会合作创办发行的全英文生物医学专业期刊,是一本同行评审的在线发表开放获取(Open Access)期刊,将及时出版基于分子角度的生物医学领域的基础研究与临床研究工作,重点关注人类疾病的发生机制、预防、诊断和治疗等方面的研究进展,力争成为生物医学领域中具有国际影响力的高质量SCI学术期刊。

本刊特点:目次收录(知网),外文期刊,

Molecular Biomedicine(国际刊号)

期刊基本信息

出版周期:年刊 级别:国际刊号
国际标准刊号:ISSN 2662-8651

杂志社联系方式

地址:四川省成都市高新区环球中心S2区6栋1103/1104/1105号
邮编:610041
官方微信公众号:四川省国际医学交流促进会(scimea)
官网邮箱:molbiomed@med-cens.org
官网邮箱:editorial@molbiomed.org
官方网站:https://www.springer.com/journal/43556

杂志征稿投稿要求

Molecular Biomedicine简介

Molecular Biomedicine 是由全球领先出版商Springer Nature发行的同行评审在线OA期刊(https://www.springer.com/journal/43556),是中国科学院院士魏于全教授主编的又一高水平生物医学期刊。同时,魏院士还创办了Signal Transduction and Targeted Therapy(简称STTT ),2020年影响因子18.187,位于SCI期刊JCR分区Q1区,全球生物化学和分子生物类期刊排名第5、细胞生物学类期刊排名第11。相信Molecular Biomedicine 有院士领队,强大编委团队支持,定是潜力无限,未来可期。

Molecular Biomedicine主编由荷兰格罗宁根大学Arnold J.M. Driessen教授(荷兰皇家科学院院士)和四川大学华西医院生物治疗国家重点实验室魏于全教授(中国科学院院士)担任。编委团队由全球10多个国家的著名科学家构成,其中超过20%为国内外院士,80%以上为国外专家,包括董晨院士、高福院士、韩家淮院士、宋伟宏院士、丁楅森教授、邓宏魁教授等著名专家教授。自开放投稿以来,始终坚持高水平、国际化、严标准的办刊策略,所有刊载内容均经过严格的同行评审,专业高效的编辑团队管理,得到了国内外同行学者的广泛认可。

目前期刊已在线发表文章50余篇,通讯国际背景接近70%,其中包括鲁汶大学Anabelle Decottignies教授、耶鲁大学Darryl T. Martin、荷兰莱顿大学Pieter Velden教授、诺丁汉大学Srinivasan Madhusudan教授、哥伦比亚大学Akiva Mintz教授、宾夕法尼亚大学徐小威教授、北达科他大学吴敏教授、四川大学黄灿华教授、中南大学陶永光、南京大学何农跃教授等全球知名专家学者稿件。

Molecular Biomedicine(简称Mol Biomed )是同行评审的在线发表开放获取 (OA) 期刊,及时出版基于分子角度的生物医学领域的基础研究与临床研究关注,重点关注人类疾病的发展机制、预防、诊断和治疗等方面的研究进展,感兴趣的主题包括表观遗传学、基因组学和蛋白质组学、基因编辑、RNA生物学、信号转导、结构生物学、疾病的早期诊断和生物标记、基因治疗、细胞治疗和免疫治疗、小分子靶向治疗、分子成像、医学人工智能、再生医学等。Molecular Biomedicine 发表论文类型包括综述(Review)、展望(Perspective)、研究论文(Research Article)、致编辑信函(Letter)、研究亮点(Research Highlight)等。Molecular Biomedicine 由衷地感谢期刊作者、审稿人和读者的巨大贡献, Molecular Biomedicine 将不断进步,发表更多高质量的论文,更好地服务于全球的读者和作者。

《Molecular Biomedicine》投稿指南

【杂志社官方网站信息】

Submission guidelines

Instructions for Authors

Article-Processing Charge

Molecular Biomedicine is an Open Access publication and an article-processing charge (APC) is levied on articles that are accepted for publication by the Editors.

The APC for this journal is covered by Sichuan International Medical Exchange & Promotion Association, in 2020-2022.

Article Types

Research

Articles describe original research, and should be 3000-6000 words (excluding the abstract, tables, figure legends and references) and contain no more than 8 display items (such as figures or tables).

Research papers should contain an unstructured abstract with up to 250 words. Additional display items will be published online as Supplemental Information.

Review

A review should be a comprehensive synthesis and/or analysis of specific topics. A short Introduction giving the rationale for the review should be followed by sections with appropriate subheadings, followed by a conclusions section at the end. The standard footer headings (Acknowledgements, Contributions, Competing Interests, and Funding) are required. All invited reviews will undergo peer review prior to acceptance.

Review papers should contain an unstructured abstract with up to 250 words, at least 3000 words in length. Review papers should contain around 4-8 figures and tables in total, around 100-500 references.

Letter

Letters provide rapid and concise report of a novel finding that is brief in nature but is of general interest to the field. There should be no more than 10 authors.

No abstract needed for Letter papers. It should include 1200 words max excluding references, figures and tables. A letter should contain, but no more than 1 display item and references are limited to 5.

Research Highlight

Research Highlights discuss the main advances made by the paper as well as putting the finds of the study into the proper context of the field.

A brief stand first of one or two sentences should serve as an abstract. A research highlight paper should include 1000 words max excluding references, figures and tables, and contain, but no more than 1 display item and references are limited to 5. A consensus should be a public statement on professional knowledge in the field of molecular biomedicine, and it is expected to be generally agreed upon as an evidence-based, state-of-the-art knowledge by a representative group of experts in that area.

Consensus

Consensus papers should contain an unstructured Abstract with up to 250 words. Four to Six Keywords representing the main content of the article. The Background section should a concise summary of a search of the existing literature and the issue under discussion. The standard footer headings (Acknowledgements, Contributions, Competing Interests, and Funding) are required.

Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit manuscript” and upload all of your manuscript files following the instructions given on the screen.

Source Files

Please ensure you provide all relevant editable source files at every submission and revision. Failing to submit a complete set of editable source files will result in your article not being considered for review. For your manuscript text please always submit in common word processing formats such as .docx or LaTeX.

……

更多详情:

https://www.springer.com/journal/43556/submission-guidelines

刊知网 精心整理,转载请注明出处:https://www.kanzhiwang.com/archives/19944

我要点评 请您把投稿经验分享出来 让大家少走弯路少踩坑,我为人人、人人为我。

内容纠错 您如果发现杂志信息有错漏 可以在下方留言。

上一篇 2024年10月23日 下午9:34
下一篇 2024年10月23日 下午9:34

相关推荐

发表回复

登录后才能评论

联系我们

191 1833 1195

在线咨询: QQ交谈

邮件:321628655@qq.com

工作时间:周一至周五,9:30-18:30,节假日休息